Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV

Virology

Volumn 403, Issue 1, 2010, Pages 92-102

  Qin, Zhiqiang ^a,b   DeFee, Michael ^b   Isaacs, Jennifer S ^a   Parsons, Chris ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Heat shock protein; Herpesvirus; Signal transduction

Indexed keywords

HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE REPRESSION; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; VIRUS GENE; VIRUS PARTICLE;

GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOCYTES; LYMPHOMA; MITOGEN-ACTIVATED PROTEIN KINASES; SARCOMA, KAPOSI;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

EID: 77953285870     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.03.052     Document Type: Article

References (62)

1. Akula S.M., Wang F.Z., Vieira J., Chandran B. Human herpesvirus 8 interaction with target cells involves heparan sulfate. Virology 2001, 282(2):245-255.
2. Aluigi M.G., Albini A., Carlone S., Repetto L., De Marchi R., Icardi A., Moro M., Noonan D., Benelli R. KSHV sequences in biopsies and cultured spindle cells of epidemic, iatrogenic and Mediterranean forms of Kaposi's sarcoma. Res. Virol. 1996, 147(5):267-275.
3. Basha W., Kitagawa R., Uhara M., Imazu H., Uechi K., Tanaka J. Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus. Antivir. Chem. Chemother. 2005, 16(2):135-146.
4. Bijlmakers M.J., Marsh M. Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck). Mol. Biol. Cell 2000, 11(5):1585-1595.
5. Birkmann A., Mahr K., Ensser A., Yaguboglu S., Titgemeyer F., Fleckenstein B., Neipel F. Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J. Virol. 2001, 75(23):11583-11593.
6. Boivin G., Gaudreau A., Routy J.P. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS 2000, 14(13):1907-1910.
7. Bonnet F., Lewden C., May T., Heripret L., Jougla E., Bevilacqua S., Costagliola D., Salmon D., Chene G., Morlat P. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004, 101(2):317-324.
8. Brown E.E., Whitby D., Vitale F., Marshall V., Mbisa G., Gamache C., Lauria C., Alberg A.J., Serraino D., Cordiali-Fei P., Messina A., Goedert J.J. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006, 107(9):2282-2290.
9. Burch A.D., Weller S.K. Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. J. Virol. 2005, 79(16):10740-10749.
10. Campbell T.B., Borok M., Gwanzura L., MaWhinney S., White I.E., Ndemera B., Gudza I., Fitzpatrick L., Schooley R.T. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000, 14(14):2109-2116.
11. Cesarman E., Chang Y., Moore P.S., Said J.W., Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 1995, 332(18):1186-1191.
12. Chaisuparat R., Hu J., Jham B.C., Knight Z.A., Shokat K.M., Montaner S. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res. 2008, 68(20):8361-8368.
13. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., Moore P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266(5192):1865-1869.
14. Cohen A., Brodie C., Sarid R. An essential role of ERK signalling in TPA-induced reactivation of Kaposi's sarcoma-associated herpesvirus. J. Gen. Virol. 2006, 87(Pt 4):795-802.
15. Connor J.H., McKenzie M.O., Parks G.D., Lyles D.S. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 2007, 362(1):109-119.
16. Dupin N., Fisher C., Kellam P., Ariad S., Tulliez M., Franck N., van Marck E., Salmon D., Gorin I., Escande J.P., Weiss R.A., Alitalo K., Boshoff C. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(8):4546-4551.
17. Engels E.A., Biggar R.J., Hall H.I., Cross H., Crutchfield A., Finch J.L., Grigg R., Hylton T., Pawlish K.S., McNeel T.S., Goedert J.J. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer 2008, 123(1):187-194.
18. Eustace B.K., Sakurai T., Stewart J.K., Yimlamai D., Unger C., Zehetmeier C., Lain B., Torella C., Henning S.W., Beste G., Scroggins B.T., Neckers L., Ilag L.L., Jay D.G. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell. Biol. 2004, 6(6):507-514.
19. Field N., Low W., Daniels M., Howell S., Daviet L., Boshoff C., Collins M. KSHV vFLIP binds to IKK-gamma to activate IKK. J. Cell. Sci. 2003, 116(Pt 18):3721-3728.
20. Ford P.W., Bryan B.A., Dyson O.F., Weidner D.A., Chintalgattu V., Akula S.M. Raf/MEK/ERK signalling triggers reactivation of Kaposi's sarcoma-associated herpesvirus latency. J. Gen. Virol. 2006, 87(Pt 5):1139-1144.
21. Galigniana M.D., Harrell J.M., O'Hagen H.M., Ljungman M., Pratt W.B. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J. Biol. Chem. 2004, 279(21):22483-22489.
22. Georgakis G.V., Li Y., Rassidakis G.Z., Martinez-Valdez H., Medeiros L.J., Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin. Cancer Res. 2006, 12(2):584-590.
23. Grundhoff A., Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J. Clin. Invest. 2004, 113(1):124-136.
24. Isaacs J.S. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?. Expert Opin Investig Drugs. 2005, 14(6):569-589.
25. Jin S., Song Y.C., Emili A., Sherman P.M., Chan V.L. JlpA of Campylobacter jejuni interacts with surface-exposed heat shock protein 90alpha and triggers signalling pathways leading to the activation of NF-kappaB and p38 MAP kinase in epithelial cells. Cell. Microbiol. 2003, 5(3):165-174.
26. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., Rosenzweig A., Salomon R.N., Van Etten R.A., Alroy J., Durand J.B., Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006, 12(8):908-916.
27. Koga F., Xu W., Karpova T.S., McNally J.G., Baron R., Neckers L. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(30):11318-11322.
28. Koon H.B., Bubley G.J., Pantanowitz L., Masiello D., Smith B., Crosby K., Proper J., Weeden W., Miller T.E., Chatis P., Egorin M.J., Tahan S.R., Dezube B.J. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 2005, 23(5):982-989.
29. Kotsiopriftis M., Tanner J.E., Alfieri C. Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in vitro. J. Virol. 2005, 79(11):7255-7261.
30. Krishnan H.H., Sharma-Walia N., Streblow D.N., Naranatt P.P., Chandran B. Focal adhesion kinase is critical for entry of Kaposi's sarcoma-associated herpesvirus into target cells. J. Virol. 2006, 80(3):1167-1180.
31. Lebbe C., de Cremoux P., Millot G., Podgorniak M.P., Verola O., Berger R., Morel P., Calvo F. Characterization of in vitro culture of HIV-negative Kaposi's sarcoma-derived cells. In vitro responses to alfa interferon. Arch. Dermatol. Res. 1997, 289(7):421-428.
32. Lebbe C., Legendre C., Frances C. Kaposi sarcoma in transplantation. Transplant. Rev. (Orlando) 2008, 22(4):252-261.
33. Li Y.H., Tao P.Z., Liu Y.Z., Jiang J.D. Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro. Antimicrob. Agents Chemother. 2004, 48(3):867-872.
34. Li Q., Zhou F., Ye F., Gao S.J. Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology 2008, 379(2):234-244.
35. Lin T.W., Lo C.W., Lai S.Y., Fan R.J., Lo C.J., Chou Y.M., Thiruvengadam R., Wang A.H., Wang M.Y. Chicken heat shock protein 90 is a component of the putative cellular receptor complex of infectious bursal disease virus. J. Virol. 2007, 81(16):8730-8741.
36. Martin D.F., Kuppermann B.D., Wolitz R.A., Palestine A.G., Li H., Robinson C.A. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N. Engl. J. Med. 1999, 340(14):1063-1070.
37. Okamoto T., Nishimura Y., Ichimura T., Suzuki K., Miyamura T., Suzuki T., Moriishi K., Matsuura Y. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J. 2006, 25(20):5015-5025.
38. Pak F., Pyakural P., Kokhaei P., Kaaya E., Pourfathollah A.A., Selivanova G., Biberfeld P. HHV-8/KSHV during the development of Kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry. J. Cutan. Pathol. 2005, 32(1):21-27.
39. Parsons C.H., Adang L.A., Overdevest J., O'Connor C.M., Taylor J.R., Camerini D., Kedes D.H. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J. Clin. Invest. 2006, 116(7):1963-1973.
40. Pyakurel P., Massambu C., Castanos-Velez E., Ericsson S., Kaaya E., Biberfeld P., Heiden T. Human herpesvirus 8/Kaposi sarcoma herpesvirus cell association during evolution of Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 2004, 36(2):678-683.
41. Qin Z., Kearney P., Plaisance K., Parsons C.H. Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J. Leukoc. Biol. 2010, 87(1):25-34.
42. Qin Z., Freitas E., Sullivan R., Mohan S., Bacelieri R., Branch D., Romano M., Kearney P., Oates J., Plaisance K., Renne R., Kaleeba J., Parsons C. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog. 2010, 6(1):e1000742.
43. Quinlivan E.B., Zhang C., Stewart P.W., Komoltri C., Davis M.G., Wehbie R.S. Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J. Infect. Dis. 2002, 185(12):1736-1744.
44. Ramalingam S.S., Egorin M.J., Ramanathan R.K., Remick S.C., Sikorski R.P., Lagattuta T.F., Chatta G.S., Friedland D.M., Stoller R.G., Potter D.M., Ivy S.P., Belani C.P. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin. Cancer Res. 2008, 14(11):3456-3461.
45. Reyes-Del Valle J., Chavez-Salinas S., Medina F., Del Angel R.M. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J. Virol. 2005, 79(8):4557-4567.
46. Sadagopan S., Sharma-Walia N., Veettil M.V., Raghu H., Sivakumar R., Bottero V., Chandran B. Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. J. Virol. 2007, 81(8):3949-3968.
47. Salahuddin S.Z., Nakamura S., Biberfeld P., Kaplan M.H., Markham P.D., Larsson L., Gallo R.C. Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science 1988, 242(4877):430-433.
48. Sharma-Walia N., Naranatt P.P., Krishnan H.H., Zeng L., Chandran B. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J. Virol. 2004, 78(8):4207-4223.
49. Sharma-Walia N., Krishnan H.H., Naranatt P.P., Zeng L., Smith M.S., Chandran B. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J. Virol. 2005, 79(16):10308-10329.
50. Sin S.H., Roy D., Wang L., Staudt M.R., Fakhari F.D., Patel D.D., Henry D., Harrington W.J., Damania B.A., Dittmer D.P. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007, 109(5):2165-2173.
51. Sodhi A., Chaisuparat R., Hu J., Ramsdell A.K., Manning B.D., Sausville E.A., Sawai E.T., Molinolo A., Gutkind J.S., Montaner S. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006, 10(2):133-143.
52. Soulier J., Grollet L., Oksenhendler E., Cacoub P., Cazals-Hatem D., Babinet P., d'Agay M.F., Clauvel J.P., Raphael M., Degos L., et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86(4):1276-1280.
53. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., Ranieri E., Gesualdo L., Schena F.P., Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 2005, 352(13):1317-1323.
54. Staskus K.A., Zhong W., Gebhard K., Herndier B., Wang H., Renne R., Beneke J., Pudney J., Anderson D.J., Ganem D., Haase A.T. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 1997, 71(1):715-719.
55. Triantafilou K., Triantafilou M., Dedrick R.L. A CD14-independent LPS receptor cluster. Nat. Immunol. 2001, 2(4):338-345.
56. Tsutsumi S., Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007, 98(10):1536-1539.
57. Tsutsumi S., Scroggins B., Koga F., Lee M.J., Trepel J., Felts S., Carreras C., Neckers L. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008, 27(17):2478-2487.
58. Vanni T., Sprinz E., Machado M.W., Santana Rde C., Fonseca B.A., Schwartsmann G. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat. Rev. 2006, 32(6):445-455.
59. Von Roenn J.H. Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol. Oncol. Clin. North Am. 2003, 17(3):747-762.
60. Xie J., Ajibade A.O., Ye F., Kuhne K., Gao S.J. Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 2008, 371(1):139-154.
61. Yu F., Harada J.N., Brown H.J., Deng H., Song M.J., Wu T.T., Kato-Stankiewicz J., Nelson C.G., Vieira J., Tamanoi F., Chanda S.K., Sun R. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS Pathog. 2007, 3(3):e44.
62. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9(1):28-39.